Summary
Therapeutic management of metastatic colorectal cancer continues to be rapidly changing. Several papers highlighted possible new treatment modalities during this year's ASCO. A selection of these will be summarized in this article. In a multidisciplinary setting, experts have recently decided to categorize mCRC patients and especially those with liver only disease into three groups: resectable patients, unresectable and most likely never curable patients and those with borderline resectable disease at presentation. The article focuses upon this selection and summarizes some new aspects presented in Chicago. The conclusion of the majority of the presentations is an individualized treatment for each patient delivered by a multidisciplinary team.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet, 371: 1007–1016, 2008
Sorbye H, Mauer M, Gruenberger T, et al. Predictive factors for the effect of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC phase III study 40983). J Clin Oncol (Meeting Abstracts), 28: 3544, 2010
Ruers T, Punt CJ, van Coevorden F, et al. Final results of the EORTC intergroup randomized study 40004 (CLOCC) evaluating the benefit of radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM). J Clin Oncol (Meeting Abstracts), 28: 3526, 2010
van Dijk TH, Havenga K, Beukema J, et al. Short-course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastases in primary stage IV rectal cancer: a phase II multicenter study of the Dutch Colorectal Cancer Group. J Clin Oncol (Meeting Abstracts), 28: 3638, 2010
Malka D, Paris E, Caramella C, et al. Hepatic arterial infusion (HAI) of oxaliplatin plus intravenous (iv) fluorouracil (FU), leucovorin (LV), and cetuximab for first-line treatment of unresectable colorectal liver metastases (CRLM) (CHOICE): a multicenter phase II study. J Clin Oncol (Meeting Abstracts), 28: 3558, 2010
Terrebonne E, Smith D, Becouarn Y, et al. Resection of colorectal cancer (CRC) metastases after bevacizumab (BV) treatment for first-line therapy: results of the ETNA cohort study. J Clin Oncol (Meeting Abstracts), 28: 3594, 2010
McCahill LE, Yothers GA, Sharif S, et al. A phase II trial of 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) chemotherapy plus bevacizumab (bev) for patients (pts) with unresectable stage IV colon cancer and a synchronous asymptomatic primary tumor: results of NSABP C-10. J Clin Oncol (Meeting Abstracts), 28: 3527, 2010
Hofheinz R, Mineur L, Greil R, et al. Panitumumab (pmab) with FOLFIRI as first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): resections and curative surgery in a phase II single arm, multicenter study (20060314). J Clin Oncol (Meeting Abstracts), 28: 3545, 2010
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Grünberger, T. Colorectal Cancer Liver Metastases (CLM) – ASCO 2010. memo 3, 178–179 (2010). https://doi.org/10.1007/s12254-010-0231-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-010-0231-6